Bais C et al. - Bevacizumab combined with frontline chemotherapy yields improved progression-free survival, but not overall survival in patients with ovarian cancer. A retrospective tumor biomarker analysis demonstrated a positive association between the density of vascular endothelial cells and tumor VEGF-A levels. The potential predictive value of microvessel density (CD31) and tumor VEGF-A is consistent with a VEGF-A signaling blockade.